207 related articles for article (PubMed ID: 34358157)
41. Bivalent H1 and H3 COBRA Recombinant Hemagglutinin Vaccines Elicit Seroprotective Antibodies against H1N1 and H3N2 Influenza Viruses from 2009 to 2019.
Allen JD; Ross TM
J Virol; 2022 Apr; 96(7):e0165221. PubMed ID: 35289635
[TBL] [Abstract][Full Text] [Related]
42. Sequential Infection in Ferrets with Antigenically Distinct Seasonal H1N1 Influenza Viruses Boosts Hemagglutinin Stalk-Specific Antibodies.
Kirchenbaum GA; Carter DM; Ross TM
J Virol; 2016 Jan; 90(2):1116-28. PubMed ID: 26559834
[TBL] [Abstract][Full Text] [Related]
43. Prime-Boost Vaccination With a Novel Hemagglutinin Protein Produced in Bacteria Induces Neutralizing Antibody Responses Against H5-Subtype Influenza Viruses in Commercial Chickens.
Sączyńska V; Romanik-Chruścielewska A; Florys K; Cecuda-Adamczewska V; Łukasiewicz N; Sokołowska I; Kęsik-Brodacka M; Płucienniczak G
Front Immunol; 2019; 10():2006. PubMed ID: 31552018
[TBL] [Abstract][Full Text] [Related]
44. Universal Influenza Virus Neuraminidase Vaccine Elicits Protective Immune Responses against Human Seasonal and Pre-pandemic Strains.
Skarlupka AL; Bebin-Blackwell AG; Sumner SF; Ross TM
J Virol; 2021 Aug; 95(17):e0075921. PubMed ID: 34160258
[TBL] [Abstract][Full Text] [Related]
45. Analysis of the vaccine-induced influenza B virus hemagglutinin-specific antibody dependent cellular cytotoxicity response.
de Vries RD; Nieuwkoop NJ; Krammer F; Hu B; Rimmelzwaan GF
Virus Res; 2020 Feb; 277():197839. PubMed ID: 31837382
[TBL] [Abstract][Full Text] [Related]
46. Unmasking Stem-Specific Neutralizing Epitopes by Abolishing N-Linked Glycosylation Sites of Influenza Virus Hemagglutinin Proteins for Vaccine Design.
Liu WC; Jan JT; Huang YJ; Chen TH; Wu SC
J Virol; 2016 Oct; 90(19):8496-508. PubMed ID: 27440889
[TBL] [Abstract][Full Text] [Related]
47. Antibody-Dependent Cell-Mediated Cytotoxicity to Hemagglutinin of Influenza A Viruses After Influenza Vaccination in Humans.
Zhong W; Liu F; Wilson JR; Holiday C; Li ZN; Bai Y; Tzeng WP; Stevens J; York IA; Levine MZ
Open Forum Infect Dis; 2016 Apr; 3(2):ofw102. PubMed ID: 27419174
[TBL] [Abstract][Full Text] [Related]
48. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine.
Corti D; Suguitan AL; Pinna D; Silacci C; Fernandez-Rodriguez BM; Vanzetta F; Santos C; Luke CJ; Torres-Velez FJ; Temperton NJ; Weiss RA; Sallusto F; Subbarao K; Lanzavecchia A
J Clin Invest; 2010 May; 120(5):1663-73. PubMed ID: 20389023
[TBL] [Abstract][Full Text] [Related]
49. Human Monoclonal Antibody 81.39a Effectively Neutralizes Emerging Influenza A Viruses of Group 1 and 2 Hemagglutinins.
Marjuki H; Mishin VP; Chai N; Tan MW; Newton EM; Tegeris J; Erlandson K; Willis M; Jones J; Davis T; Stevens J; Gubareva LV
J Virol; 2016 Dec; 90(23):10446-10458. PubMed ID: 27630240
[TBL] [Abstract][Full Text] [Related]
50. An Improved Inactivated Influenza Vaccine with Enhanced Cross Protection.
Ni Y; Guo J; Turner D; Tizard I
Front Immunol; 2018; 9():1815. PubMed ID: 30140267
[TBL] [Abstract][Full Text] [Related]
51. Modified vaccinia virus Ankara encoding influenza virus hemagglutinin induces heterosubtypic immunity in macaques.
Florek KR; Weinfurter JT; Jegaskanda S; Brewoo JN; Powell TD; Young GR; Das SC; Hatta M; Broman KW; Hungnes O; Dudman SG; Kawaoka Y; Kent SJ; Stinchcomb DT; Osorio JE; Friedrich TC
J Virol; 2014 Nov; 88(22):13418-28. PubMed ID: 25210172
[TBL] [Abstract][Full Text] [Related]
52. HA1 (Hemagglutinin) quantitation for influenza A H1N1 and H3N2 high yield reassortant vaccine candidate seed viruses by RP-UPLC.
Fulvini AA; Tuteja A; Le J; Pokorny BA; Silverman J; Bucher D
Vaccine; 2021 Jan; 39(3):545-553. PubMed ID: 33341306
[TBL] [Abstract][Full Text] [Related]
53. Cross-reactive mouse monoclonal antibodies raised against the hemagglutinin of A/Shanghai/1/2013 (H7N9) protect against novel H7 virus isolates in the mouse model.
Stadlbauer D; Amanat F; Strohmeier S; Nachbagauer R; Krammer F
Emerg Microbes Infect; 2018 Jun; 7(1):110. PubMed ID: 29925896
[TBL] [Abstract][Full Text] [Related]
54. Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans.
Ellebedy AH; Krammer F; Li GM; Miller MS; Chiu C; Wrammert J; Chang CY; Davis CW; McCausland M; Elbein R; Edupuganti S; Spearman P; Andrews SF; Wilson PC; García-Sastre A; Mulligan MJ; Mehta AK; Palese P; Ahmed R
Proc Natl Acad Sci U S A; 2014 Sep; 111(36):13133-8. PubMed ID: 25157133
[TBL] [Abstract][Full Text] [Related]
55. Surveillance Study of Influenza Occurrence and Immunity in a Wisconsin Cohort During the 2009 Pandemic.
Lo CY; Strobl SL; Dunham K; Wang W; Stewart L; Misplon JA; Garcia M; Gao J; Ozawa T; Price GE; Navidad J; Gradus S; Bhattacharyya S; Viboud C; Eichelberger MC; Weiss CD; Gorski J; Epstein SL
Open Forum Infect Dis; 2017; 4(2):ofx023. PubMed ID: 28730155
[TBL] [Abstract][Full Text] [Related]
56. H5 N-terminal β sheet promotes oligomerization of H7-HA1 that induces better antibody affinity maturation and enhanced protection against H7N7 and H7N9 viruses compared to inactivated influenza vaccine.
Khurana S; Coyle EM; Verma S; King LR; Manischewitz J; Crevar CJ; Carter DM; Ross TM; Golding H
Vaccine; 2014 Nov; 32(48):6421-32. PubMed ID: 25284811
[TBL] [Abstract][Full Text] [Related]
57. Characterization and use in neutralization assays of avian influenza codon-optimized H5 and H7 retroviral pseudotypes.
Delgadillo-Gutiérrez K; Castelán-Vega JA; Jiménez-Alberto A; Fernández-Lizárraga MDC; Aparicio-Ozores G; Monterrubio-López GP; Ribas-Aparicio RM
J Virol Methods; 2022 Feb; 300():114391. PubMed ID: 34890710
[TBL] [Abstract][Full Text] [Related]
58. Imprinted Anti-Hemagglutinin and Anti-Neuraminidase Antibody Responses after Childhood Infections of A(H1N1) and A(H1N1)pdm09 Influenza Viruses.
Daulagala P; Mann BR; Leung K; Lau EHY; Yung L; Lei R; Nizami SIN; Wu JT; Chiu SS; Daniels RS; Wu NC; Wentworth D; Peiris M; Yen HL
mBio; 2023 Jun; 14(3):e0008423. PubMed ID: 37070986
[TBL] [Abstract][Full Text] [Related]
59. A critical HA1 neutralizing domain of H5N1 influenza in an optimal conformation induces strong cross-protection.
Du L; Zhao G; Sun S; Zhang X; Zhou X; Guo Y; Li Y; Zhou Y; Jiang S
PLoS One; 2013; 8(1):e53568. PubMed ID: 23320093
[TBL] [Abstract][Full Text] [Related]
60. Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells.
Li GM; Chiu C; Wrammert J; McCausland M; Andrews SF; Zheng NY; Lee JH; Huang M; Qu X; Edupuganti S; Mulligan M; Das SR; Yewdell JW; Mehta AK; Wilson PC; Ahmed R
Proc Natl Acad Sci U S A; 2012 Jun; 109(23):9047-52. PubMed ID: 22615367
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
